References
- Kyle R. A., Rajkumar S. V. Monoclonal gammopathy of undetermined significance: a review. Immunol Rev 2003; 194: 112–39
- Garton M. J., Keir G., Dickie A., Steven M., Rennie J. A. N. Prevalence and long‐term significance of paraproteinaemia in rheumatoid arthritis. Rheumatology 2006; 45: 355–6
- Tsimberidou A‐M., Waddelow T., Kantarjian H. M., Albitar M., Giles F. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNFα levels during treatment. Leuk Res 2003; 27: 375–80
- Kast R. E. Evidence for a mechanism by which etanercept increased TNF‐alpha in multiple myeloma: new insights into the biology of TNF‐alpha giving new treatment opportunities: the role of bupropion. Leuk Res 2005; 29: 1459–63
- Ledingham J., Deighton C., British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidance of April 2001). Rheumatology 2005; 44: 157–63
- Cohen S. B., Emery P., Greenwald M. W., Dougados M., Furie R. A., Genovese M. C., et al. Rituximab for rheumatoid arthritis refractory to anti‐tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks. Arthritis Rheum 2006; 54: 2793–806